Equaltox, LLC

Equaltox, LLC was paid $7.28M by Medicaid between Jan 2018 and Nov 2024, across 52 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 71% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in California

Rank by total paid#86 of 561

Median peer was paid$222K

This provider vs. median33×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	945	$144K
2019	2,557	$371K
2020	23,536	$904K
2021	32,592	$1.47M
2022	30,552	$1.31M
2023	21,066	$1.31M
2024incomplete	26,773	$1.78M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	71%	36,591	16,980	$5.15M
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	13%	13,177	11,501	$912K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	3.7%	8,337	4,020	$266K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	3.4%	12,913	11,192	$247K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	1,583	812	$71K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	3,153	3,134	$58K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	3,588	3,354	$55K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	2,003	1,899	$48K
84403		<1%	1,867	1,864	$32K
82728		<1%	2,873	2,868	$32K
84443	Thyroid stimulating hormone (TSH)	<1%	2,973	2,955	$31K
80061	Lipid panel	<1%	3,049	3,018	$29K

40 more codes

84439		<1%	3,061	$24K
82670		<1%	1,318	$24K
83036	Hemoglobin; glycosylated (A1C)	<1%	3,307	$24K
80053	Comprehensive metabolic panel	<1%	3,032	$24K
84480		<1%	1,892	$21K
82747		<1%	2,014	$20K
84144		<1%	1,297	$18K
86141		<1%	1,978	$18K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	652	$17K
83540		<1%	3,010	$15K
83735		<1%	2,989	$14K
82043		<1%	2,047	$14K
84100		<1%	3,058	$13K
86430		<1%	1,958	$13K
84550		<1%	2,087	$12K
82150		<1%	1,974	$10K
80050	General health panel	<1%	701	$8K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	445	$8K
86592		<1%	2,379	$7K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	77	$6K
81003		<1%	477	$6K
83550		<1%	858	$5K
84436		<1%	676	$5K
84702		<1%	435	$5K
82607		<1%	556	$4K
85652		<1%	2,007	$4K
86762		<1%	305	$3K
87340		<1%	334	$3K
84153		<1%	103	$1K
85045		<1%	373	$1K
83001		<1%	36	$549.00
80074		<1%	13	$418.32
82947		<1%	121	$357.69
82570		<1%	201	$263.67
86803		<1%	19	$223.92
86705		<1%	20	$195.13
86709		<1%	20	$186.39
84146		<1%	36	$148.04
81001		0%	12	$0.00
83002		0%	36	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialSCOTT, CRANFORD (MEDICAL DIRECTOR)

Same official

Other billing entities under SCOTT, CRANFORD

Full network →

Provider	Location	Paid
Meiheir Medical Group, PC	Inglewood, CA	$16K
Scergon Medical Group Limited, Apc	Inglewood, CA	$286.15

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.